Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT07455734

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Sponsor: BioNTech (Shanghai) Pharmaceuticals Co., Ltd.

Conditions Advanced Solid Tumor Cancer

Interventions BNT3214

Updated 1 time since 2026 Last updated: Mar 3, 2026 Started: Mar 31, 2026 Primary completion: Oct 31, 2030 Completion: Oct 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07455734, this PHASE1/PHASE2 trial focuses on Advanced Solid Tumor Cancer and remains actively recruiting participants. Sponsored by BioNTech (Shanghai) Pharmaceuticals Co., Ltd., it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE1/PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
BioNTech SE
Biotheus (Hengqin) Co., Ltd.

Data source: BioNTech SE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.